- Home
- SNRE vs CRSP Comparison
SNRE vs CRSP Comparison
Compare SNRE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNRE
- CRSP
- Stock Information
- Founded
- SNRE 2000
- CRSP 2013
- Country
- SNRE Switzerland
- CRSP Switzerland
- Employees
- SNRE N/A
- CRSP N/A
- Industry
- SNRE Cable & Other Pay Television Services
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNRE Telecommunications
- CRSP Health Care
- Exchange
- SNRE Nasdaq
- CRSP Nasdaq
- Market Cap
- SNRE 3.7B
- CRSP 4.0B
- IPO Year
- SNRE N/A
- CRSP 2016
- Fundamental
- Price
- SNRE $56.18
- CRSP $52.16
- Analyst Decision
- SNRE
- CRSP Buy
- Analyst Count
- SNRE 0
- CRSP 17
- Target Price
- SNRE N/A
- CRSP $71.20
- AVG Volume (30 Days)
- SNRE 180.8K
- CRSP 3.6M
- Earning Date
- SNRE 08-18-2025
- CRSP 08-04-2025
- Dividend Yield
- SNRE 7.01%
- CRSP N/A
- EPS Growth
- SNRE N/A
- CRSP N/A
- EPS
- SNRE N/A
- CRSP N/A
- Revenue
- SNRE $3,386,277,504.00
- CRSP $37,675,000.00
- Revenue This Year
- SNRE N/A
- CRSP $30.25
- Revenue Next Year
- SNRE N/A
- CRSP $268.62
- P/E Ratio
- SNRE N/A
- CRSP N/A
- Revenue Growth
- SNRE N/A
- CRSP N/A
- 52 Week Low
- SNRE $42.51
- CRSP $30.04
- 52 Week High
- SNRE $57.02
- CRSP $63.68
- Technical
- Relative Strength Index (RSI)
- SNRE N/A
- CRSP 80.27
- Support Level
- SNRE N/A
- CRSP $46.60
- Resistance Level
- SNRE N/A
- CRSP $51.52
- Average True Range (ATR)
- SNRE 0.00
- CRSP 2.55
- MACD
- SNRE 0.00
- CRSP 0.66
- Stochastic Oscillator
- SNRE 0.00
- CRSP 93.04
About SNRE Sunrise Communications AG American Depositary Shares representing Class A shares
Sunrise Communications AG is a telecommunications company. The company provides high-quality mobile, landline, broadband, and TV services to residential customers. The company also offers business customers 360-degree communications solutions and integrated ICT solutions for connectivity, security, and IoT from a single source to take companies forward in their quest for digitalization. It has three reportable segments being Residential customers; Business customers and Wholesale and Infrastructure and Support functions.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.